Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Profile

Thomas Flaig

Concepts (382)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Urinary Bladder Neoplasms
37
2024
196
9.300
 Why?
Prostatic Neoplasms
36
2022
921
5.900
 Why?
Kidney Neoplasms
23
2023
327
3.950
 Why?
Prostatic Neoplasms, Castration-Resistant
18
2021
40
3.850
 Why?
Antineoplastic Agents
28
2021
1879
3.540
 Why?
Antineoplastic Combined Chemotherapy Protocols
26
2022
1355
3.510
 Why?
Carcinoma, Renal Cell
18
2023
168
3.480
 Why?
Carcinoma, Transitional Cell
12
2024
53
3.300
 Why?
Androgen Antagonists
14
2020
69
2.620
 Why?
Pyrroles
7
2017
181
1.690
 Why?
Neoadjuvant Therapy
8
2024
304
1.680
 Why?
Indoles
7
2017
304
1.560
 Why?
Medical Oncology
5
2020
229
1.460
 Why?
Urologic Neoplasms
6
2023
25
1.420
 Why?
Neoplasm Metastasis
24
2021
523
1.390
 Why?
Abiraterone Acetate
9
2021
14
1.360
 Why?
Urothelium
3
2016
33
1.320
 Why?
Adenocarcinoma
7
2020
795
1.180
 Why?
Prednisone
14
2021
229
1.180
 Why?
Taxoids
7
2017
93
1.150
 Why?
Phenylurea Compounds
6
2016
82
1.140
 Why?
Neoplasm Staging
13
2023
1167
1.120
 Why?
Antineoplastic Agents, Hormonal
8
2017
138
1.110
 Why?
Mitoxantrone
5
2018
12
1.100
 Why?
Niacinamide
5
2016
63
1.060
 Why?
Prostate-Specific Antigen
11
2022
151
1.040
 Why?
Male
86
2023
55606
1.030
 Why?
Orchiectomy
4
2014
57
1.010
 Why?
Cisplatin
11
2024
262
0.970
 Why?
Humans
125
2024
114698
0.960
 Why?
Antibodies, Monoclonal, Humanized
8
2024
663
0.920
 Why?
Penile Neoplasms
1
2023
7
0.870
 Why?
Aged
52
2022
19074
0.850
 Why?
Phenylthiohydantoin
6
2021
40
0.810
 Why?
Carcinoma
2
2016
198
0.810
 Why?
Testicular Neoplasms
3
2023
96
0.790
 Why?
ErbB Receptors
6
2018
554
0.760
 Why?
Treatment Outcome
28
2023
9088
0.760
 Why?
Immunotherapy
5
2022
474
0.750
 Why?
Protein Kinase Inhibitors
6
2014
785
0.740
 Why?
Nitriles
10
2021
149
0.710
 Why?
Neoplasm Invasiveness
6
2024
442
0.710
 Why?
Aged, 80 and over
25
2021
6347
0.700
 Why?
Radiosurgery
4
2015
299
0.660
 Why?
Disease-Free Survival
12
2017
620
0.620
 Why?
Bone Neoplasms
3
2015
194
0.610
 Why?
Sulfonamides
2
2012
445
0.610
 Why?
Cystectomy
5
2024
32
0.600
 Why?
Middle Aged
41
2021
26738
0.590
 Why?
Viscera
2
2014
15
0.590
 Why?
Hematologic Diseases
2
2016
55
0.580
 Why?
Prostatectomy
5
2018
98
0.560
 Why?
Antineoplastic Agents, Immunological
2
2020
152
0.560
 Why?
Urinary Bladder
3
2023
162
0.560
 Why?
Benzamides
7
2021
169
0.550
 Why?
Practice Guidelines as Topic
3
2019
1395
0.550
 Why?
Erythrocytes, Abnormal
1
2016
12
0.550
 Why?
Liver Neoplasms
3
2017
506
0.540
 Why?
Prognosis
12
2023
3329
0.540
 Why?
Receptors, Androgen
2
2021
131
0.510
 Why?
Pancreatitis
1
2016
107
0.510
 Why?
Genomics
2
2018
635
0.510
 Why?
Silymarin
4
2013
194
0.470
 Why?
Leydig Cell Tumor
1
2014
8
0.460
 Why?
Epithelial-Mesenchymal Transition
2
2016
167
0.440
 Why?
Multicenter Studies as Topic
2
2021
249
0.420
 Why?
Chemotherapy, Adjuvant
7
2023
332
0.420
 Why?
Proto-Oncogene Proteins p21(ras)
1
2013
228
0.410
 Why?
Gene Expression Profiling
1
2018
1518
0.400
 Why?
Hypothyroidism
1
2012
64
0.400
 Why?
Administration, Intravesical
3
2022
14
0.390
 Why?
Carcinoma, Basal Cell
1
2013
68
0.390
 Why?
Sarcoma
1
2013
137
0.390
 Why?
Neoplasms, Germ Cell and Embryonal
2
2023
62
0.390
 Why?
Therapies, Investigational
1
2011
14
0.390
 Why?
Diethylstilbestrol
1
2011
8
0.380
 Why?
Angiomyolipoma
1
2011
17
0.380
 Why?
Antibodies, Monoclonal
5
2024
1262
0.380
 Why?
Receptors, Vascular Endothelial Growth Factor
2
2013
103
0.370
 Why?
Disease Progression
10
2021
2380
0.370
 Why?
Pyrazoles
2
2023
362
0.370
 Why?
Leukemia, Myeloid, Acute
2
2008
534
0.360
 Why?
Lung Neoplasms
5
2017
2177
0.360
 Why?
Neoplastic Cells, Circulating
1
2011
59
0.360
 Why?
Androstenes
4
2015
11
0.350
 Why?
Retrospective Studies
12
2024
12555
0.350
 Why?
Molecular Targeted Therapy
1
2013
347
0.350
 Why?
United States
10
2023
12186
0.340
 Why?
Adult
25
2021
30553
0.340
 Why?
Receptors, Fibroblast Growth Factor
1
2010
63
0.340
 Why?
Neoplasm Proteins
1
2013
385
0.340
 Why?
Recombinant Fusion Proteins
1
2012
616
0.340
 Why?
Kaplan-Meier Estimate
8
2016
811
0.340
 Why?
Tumor Suppressor Protein p53
1
2013
445
0.340
 Why?
Neoplasms, Multiple Primary
1
2010
52
0.330
 Why?
SEER Program
4
2023
196
0.330
 Why?
Antineoplastic Agents, Phytogenic
2
2010
181
0.330
 Why?
Neoplasm Recurrence, Local
4
2022
858
0.330
 Why?
Lymphatic Diseases
1
2009
17
0.320
 Why?
Neuroblastoma
1
2010
133
0.320
 Why?
Vascular Endothelial Growth Factors
1
2009
61
0.320
 Why?
Cystitis
1
2009
20
0.320
 Why?
Survival Rate
9
2021
1644
0.320
 Why?
Vascular Endothelial Growth Factor A
2
2019
498
0.320
 Why?
Double-Blind Method
12
2021
1660
0.310
 Why?
Female
26
2021
59520
0.310
 Why?
Androstadienes
3
2013
97
0.300
 Why?
Precision Medicine
1
2011
337
0.300
 Why?
Pneumatosis Cystoides Intestinalis
1
2008
19
0.300
 Why?
Intestinal Perforation
1
2008
39
0.300
 Why?
Clinical Trials as Topic
5
2018
932
0.300
 Why?
Pyrimidines
1
2011
376
0.300
 Why?
Deoxycytidine
3
2024
138
0.300
 Why?
Muscles
3
2024
320
0.300
 Why?
Carcinoma, Squamous Cell
1
2013
577
0.300
 Why?
Pancreatic Neoplasms
1
2014
731
0.290
 Why?
Testosterone
3
2021
343
0.290
 Why?
Survival Analysis
6
2021
1211
0.280
 Why?
BCG Vaccine
2
2018
18
0.280
 Why?
Androgen Receptor Antagonists
3
2021
30
0.270
 Why?
Combined Modality Therapy
9
2020
1121
0.270
 Why?
Cell Line, Tumor
7
2018
2710
0.270
 Why?
Nanotubes
2
2018
41
0.270
 Why?
Quinazolines
4
2019
240
0.270
 Why?
Neoplasm Grading
6
2018
242
0.260
 Why?
Carboplatin
1
2006
135
0.260
 Why?
Gold
2
2018
106
0.260
 Why?
Skin Neoplasms
1
2013
756
0.250
 Why?
Tumor Microenvironment
3
2023
430
0.250
 Why?
Lymphatic Metastasis
2
2018
275
0.250
 Why?
Gonadotropin-Releasing Hormone
2
2020
188
0.250
 Why?
Drug Resistance, Neoplasm
3
2018
636
0.250
 Why?
Biomarkers, Tumor
4
2023
1040
0.240
 Why?
Randomized Controlled Trials as Topic
3
2021
1214
0.240
 Why?
Societies, Medical
2
2018
664
0.230
 Why?
Radiotherapy, Adjuvant
2
2018
182
0.230
 Why?
Drug Synergism
3
2011
316
0.230
 Why?
Dexamethasone
1
2006
317
0.230
 Why?
Androstenols
3
2015
4
0.220
 Why?
Dose-Response Relationship, Drug
5
2013
1842
0.220
 Why?
Tosyl Compounds
4
2018
14
0.220
 Why?
Drug Administration Schedule
4
2021
718
0.220
 Why?
Gene Expression Regulation, Neoplastic
2
2021
1141
0.210
 Why?
Vitamin D
1
2006
341
0.210
 Why?
Steroid 17-alpha-Hydroxylase
2
2014
4
0.210
 Why?
Cell-Free Nucleic Acids
1
2023
26
0.210
 Why?
Anilides
4
2018
67
0.210
 Why?
Quality of Life
4
2024
2353
0.200
 Why?
Sleep Initiation and Maintenance Disorders
1
2024
119
0.200
 Why?
Patient Reported Outcome Measures
2
2024
250
0.200
 Why?
Retroperitoneal Space
1
2021
15
0.200
 Why?
Thiohydantoins
1
2021
2
0.190
 Why?
Indazoles
2
2012
58
0.190
 Why?
Tissue Extracts
2
2012
20
0.190
 Why?
Databases, Factual
2
2016
1125
0.190
 Why?
Kallikreins
2
2019
30
0.190
 Why?
Retreatment
1
2021
67
0.180
 Why?
Bone Marrow Transplantation
1
2002
239
0.180
 Why?
Tomography, X-Ray Computed
4
2014
2286
0.180
 Why?
Time Factors
5
2020
6116
0.170
 Why?
Genetic Heterogeneity
1
2020
48
0.170
 Why?
Phosphatidylcholines
2
2013
133
0.170
 Why?
Angiogenesis Inhibitors
2
2021
214
0.160
 Why?
In Situ Hybridization, Fluorescence
2
2011
309
0.160
 Why?
Yttrium
1
2018
5
0.160
 Why?
Cell Adhesion Molecules
1
2020
168
0.160
 Why?
Fluorides
1
2018
43
0.160
 Why?
Euterpe
1
2018
5
0.160
 Why?
Central Nervous System
1
2020
235
0.150
 Why?
Piperidines
2
2010
160
0.150
 Why?
Organ Sparing Treatments
1
2018
31
0.150
 Why?
Costimulatory and Inhibitory T-Cell Receptors
1
2018
7
0.150
 Why?
Lymph Node Excision
2
2021
139
0.150
 Why?
Odds Ratio
1
2021
953
0.150
 Why?
Congresses as Topic
2
2012
195
0.150
 Why?
Apoptosis
1
2007
2363
0.150
 Why?
Antioxidants
2
2013
530
0.150
 Why?
History, 21st Century
2
2015
159
0.150
 Why?
Tumor Escape
1
2018
35
0.150
 Why?
Cancer Vaccines
1
2019
137
0.150
 Why?
Genome
1
2020
271
0.150
 Why?
Neoplasm, Residual
2
2021
104
0.150
 Why?
Microscopy, Fluorescence
3
2018
396
0.140
 Why?
Proton Therapy
1
2017
10
0.140
 Why?
Blotting, Western
2
2010
1147
0.140
 Why?
Practice Patterns, Physicians'
2
2016
1177
0.140
 Why?
Goserelin
3
2018
8
0.140
 Why?
Biopsy
3
2018
1036
0.140
 Why?
Erythrocyte Indices
1
2016
27
0.140
 Why?
Plant Extracts
1
2018
154
0.140
 Why?
Aftercare
1
2018
186
0.140
 Why?
Oligopeptides
1
2018
236
0.130
 Why?
Dyslipidemias
1
2018
154
0.130
 Why?
Fatal Outcome
2
2008
284
0.130
 Why?
Watchful Waiting
1
2016
55
0.130
 Why?
Adverse Drug Reaction Reporting Systems
1
2016
68
0.130
 Why?
High-Throughput Nucleotide Sequencing
1
2018
439
0.130
 Why?
United States Food and Drug Administration
1
2016
172
0.130
 Why?
Prostate
2
2021
156
0.120
 Why?
Disease Management
1
2019
560
0.120
 Why?
Nanoparticles
1
2018
313
0.120
 Why?
Patient Selection
1
2018
641
0.120
 Why?
Soft Tissue Neoplasms
1
2015
90
0.120
 Why?
Radiation Tolerance
1
2015
92
0.120
 Why?
Insurance, Health
1
2016
244
0.120
 Why?
Cytochrome P-450 Enzyme Inhibitors
1
2014
4
0.120
 Why?
Ablation Techniques
1
2014
29
0.120
 Why?
Mitotic Index
1
2014
26
0.110
 Why?
Neoplasms, Hormone-Dependent
1
2014
38
0.110
 Why?
Magnetic Resonance Imaging
3
2021
3053
0.110
 Why?
Hyperthermia, Induced
1
2014
65
0.110
 Why?
Glucocorticoids
1
2018
532
0.110
 Why?
Neoplasms, Complex and Mixed
1
2013
7
0.110
 Why?
Carcinoma, Medullary
1
2013
13
0.110
 Why?
Receptor, ErbB-2
1
2016
300
0.110
 Why?
beta-Galactosidase
1
2013
62
0.110
 Why?
Breeding
1
2013
55
0.110
 Why?
Sirolimus
2
2014
181
0.110
 Why?
Geriatrics
1
2014
69
0.110
 Why?
Reproducibility of Results
2
2013
2765
0.110
 Why?
Brain Neoplasms
1
2021
979
0.110
 Why?
Interleukin-2
1
2014
413
0.110
 Why?
Staining and Labeling
1
2013
134
0.110
 Why?
Hyperplasia
1
2013
163
0.110
 Why?
Cell Proliferation
2
2012
2187
0.110
 Why?
Keratins
1
2013
176
0.110
 Why?
Urogenital Neoplasms
1
2012
5
0.110
 Why?
Tumor Stem Cell Assay
1
2012
33
0.100
 Why?
Nephrectomy
2
2013
150
0.100
 Why?
Population Surveillance
1
2015
392
0.100
 Why?
Organ Specificity
1
2013
268
0.100
 Why?
Adenoviridae
1
2013
184
0.100
 Why?
Integrases
1
2013
116
0.100
 Why?
Fluorescent Antibody Technique
1
2013
397
0.100
 Why?
Celecoxib
1
2012
38
0.100
 Why?
Thyroid Hormones
1
2012
53
0.100
 Why?
Thyroid Gland
1
2012
82
0.100
 Why?
Quinolines
1
2013
129
0.100
 Why?
RNA, Untranslated
1
2013
113
0.100
 Why?
Bone Diseases
1
2012
57
0.100
 Why?
Cross-Over Studies
3
2021
440
0.100
 Why?
Reoperation
1
2014
514
0.100
 Why?
Carcinoma, Hepatocellular
1
2013
211
0.100
 Why?
Imidazoles
1
2012
208
0.090
 Why?
Denosumab
1
2010
7
0.090
 Why?
PubMed
1
2010
10
0.090
 Why?
RANK Ligand
1
2010
26
0.090
 Why?
Animals
5
2016
31708
0.090
 Why?
Benzenesulfonates
1
2010
20
0.090
 Why?
Neoplasms
2
2022
2097
0.090
 Why?
Erlotinib Hydrochloride
1
2010
64
0.090
 Why?
Vimentin
1
2010
58
0.090
 Why?
Insulin-Like Growth Factor Binding Protein 3
1
2010
38
0.090
 Why?
Xenograft Model Antitumor Assays
1
2012
698
0.090
 Why?
Cell Separation
1
2011
291
0.090
 Why?
Hypertension
1
2018
1056
0.090
 Why?
Mesoderm
1
2010
138
0.080
 Why?
Cardiovascular Diseases
2
2018
1727
0.080
 Why?
Tumor Cells, Cultured
1
2011
849
0.080
 Why?
Cadherins
1
2010
175
0.080
 Why?
Carcinoma, Papillary
1
2009
73
0.080
 Why?
Age Factors
1
2016
2894
0.080
 Why?
Nephrolithiasis
1
2009
10
0.080
 Why?
Metaplasia
1
2009
54
0.080
 Why?
Gynecomastia
1
2008
4
0.080
 Why?
Risk Factors
5
2018
8632
0.080
 Why?
Chromatography, Liquid
1
2010
347
0.080
 Why?
Risk
1
2011
812
0.080
 Why?
Genotype
1
2013
1760
0.080
 Why?
Mice, Transgenic
1
2013
1950
0.080
 Why?
Drug Therapy, Combination
1
2011
951
0.080
 Why?
Proportional Hazards Models
3
2016
1075
0.080
 Why?
Tandem Mass Spectrometry
1
2010
412
0.070
 Why?
Insulin-Like Growth Factor I
1
2010
286
0.070
 Why?
Southwestern United States
1
2008
91
0.070
 Why?
Liver Failure, Acute
1
2008
58
0.070
 Why?
Hormone Replacement Therapy
1
2008
77
0.070
 Why?
Mediastinal Diseases
1
2007
9
0.070
 Why?
Carcinoid Tumor
1
2007
25
0.070
 Why?
Mice
2
2013
14871
0.070
 Why?
Pyridines
1
2010
425
0.070
 Why?
Glucuronides
1
2006
12
0.070
 Why?
Neoplasms, Second Primary
1
2008
92
0.070
 Why?
Spectrophotometry, Ultraviolet
1
2006
73
0.070
 Why?
Medical History Taking
1
2007
114
0.070
 Why?
Excipients
1
2006
49
0.070
 Why?
Liver Function Tests
1
2006
103
0.070
 Why?
Chemistry, Pharmaceutical
1
2006
98
0.070
 Why?
Syndrome
1
2007
333
0.070
 Why?
Antibiotics, Antineoplastic
1
2006
109
0.070
 Why?
Spectrometry, Mass, Electrospray Ionization
1
2006
162
0.070
 Why?
Pedigree
1
2007
460
0.060
 Why?
Sarcoidosis
1
2007
135
0.060
 Why?
Everolimus
2
2017
61
0.060
 Why?
Radiography
1
2008
812
0.060
 Why?
Signal Transduction
2
2016
4515
0.060
 Why?
Doxorubicin
1
2006
285
0.060
 Why?
Forecasting
1
2007
330
0.060
 Why?
Metabolic Syndrome
1
2008
321
0.060
 Why?
Biomarkers
2
2023
3408
0.060
 Why?
Epithelial Cells
1
2010
951
0.060
 Why?
Melanoma
1
2011
620
0.060
 Why?
DNA Damage
1
2007
351
0.060
 Why?
Diagnosis, Differential
1
2009
1342
0.060
 Why?
Gastrointestinal Diseases
1
2006
182
0.060
 Why?
Referral and Consultation
1
2009
635
0.060
 Why?
Radiotherapy
2
2015
176
0.060
 Why?
Carcinoma, Non-Small-Cell Lung
1
2012
961
0.060
 Why?
Young Adult
4
2021
10471
0.050
 Why?
Disease Models, Animal
1
2012
3535
0.050
 Why?
Follow-Up Studies
2
2015
4411
0.050
 Why?
Immunohistochemistry
2
2020
1629
0.050
 Why?
Maximum Tolerated Dose
2
2013
183
0.050
 Why?
Immune System Diseases
1
2002
32
0.050
 Why?
Steroid Synthesis Inhibitors
1
2021
1
0.050
 Why?
Policy
1
2022
137
0.050
 Why?
Proteomics
1
2007
836
0.050
 Why?
Clinical Trials, Phase III as Topic
1
2021
82
0.050
 Why?
Mass Screening
1
2008
1005
0.050
 Why?
Prednisolone
1
2021
75
0.050
 Why?
Metabolic Diseases
1
2002
98
0.050
 Why?
Tumor Burden
1
2021
259
0.050
 Why?
Bevacizumab
1
2021
115
0.040
 Why?
Phosphatidylinositol 3-Kinases
1
2022
329
0.040
 Why?
Proto-Oncogene Proteins c-akt
1
2022
398
0.040
 Why?
Asymptomatic Diseases
1
2021
75
0.040
 Why?
TOR Serine-Threonine Kinases
1
2022
360
0.040
 Why?
Neovascularization, Pathologic
1
2021
281
0.040
 Why?
Ytterbium
1
2018
2
0.040
 Why?
Hospitals
1
2023
581
0.040
 Why?
Erbium
1
2018
5
0.040
 Why?
HLA-A2 Antigen
1
2019
36
0.040
 Why?
Estrogen Receptor alpha
1
2020
121
0.040
 Why?
Risk Assessment
1
2008
2968
0.040
 Why?
DNA Methylation
1
2023
495
0.040
 Why?
Drug-Related Side Effects and Adverse Reactions
1
2021
238
0.040
 Why?
Fruit and Vegetable Juices
1
2018
11
0.040
 Why?
Granulocyte-Macrophage Colony-Stimulating Factor
1
2019
140
0.040
 Why?
Luminescent Measurements
1
2018
74
0.040
 Why?
Pain
1
2024
705
0.040
 Why?
Lasers
1
2018
121
0.040
 Why?
Laparoscopy
1
2021
398
0.040
 Why?
National Cancer Institute (U.S.)
1
2017
40
0.030
 Why?
Antibodies
1
2018
371
0.030
 Why?
Risk Reduction Behavior
1
2018
201
0.030
 Why?
DNA
1
2023
1352
0.030
 Why?
Abdominal Neoplasms
1
2015
26
0.030
 Why?
Molecular Diagnostic Techniques
1
2016
91
0.030
 Why?
Thoracic Neoplasms
1
2015
32
0.030
 Why?
Placebos
1
2015
197
0.030
 Why?
Radiotherapy Planning, Computer-Assisted
1
2015
117
0.030
 Why?
Administration, Oral
1
2017
728
0.030
 Why?
Antihypertensive Agents
1
2018
429
0.030
 Why?
Nanoconjugates
1
2014
1
0.030
 Why?
Spectrophotometry, Atomic
1
2014
13
0.030
 Why?
Platelet Aggregation Inhibitors
1
2018
401
0.030
 Why?
Lipids
1
2018
580
0.030
 Why?
Radiotherapy, Intensity-Modulated
1
2015
124
0.030
 Why?
Smoking Cessation
1
2018
374
0.030
 Why?
Hydroxymethylglutaryl-CoA Reductase Inhibitors
1
2018
373
0.030
 Why?
Benchmarking
1
2015
161
0.030
 Why?
Accidental Falls
1
2015
151
0.030
 Why?
Cell Death
1
2014
323
0.030
 Why?
Prospective Studies
1
2023
6220
0.020
 Why?
Blood Pressure
1
2018
1538
0.020
 Why?
Hydroxamic Acids
1
2012
80
0.020
 Why?
Health Policy
1
2014
334
0.020
 Why?
Dose-Response Relationship, Radiation
1
2011
127
0.020
 Why?
Histone Deacetylase Inhibitors
1
2012
198
0.020
 Why?
Androgens
1
2011
167
0.020
 Why?
Polyethylene Glycols
1
2014
561
0.020
 Why?
Seizures
1
2012
340
0.020
 Why?
Fatigue
1
2011
294
0.020
 Why?
Sex Factors
1
2014
1715
0.020
 Why?
Multivariate Analysis
1
2012
1430
0.020
 Why?
Positron-Emission Tomography
1
2009
259
0.020
 Why?
Radionuclide Imaging
1
2007
115
0.020
 Why?
Cell Membrane Permeability
1
2006
83
0.020
 Why?
Head and Neck Neoplasms
1
2008
427
0.010
 Why?
Cell Survival
1
2006
1021
0.010
 Why?
Ultrasonography
1
2006
634
0.010
 Why?
Incidence
1
2008
2313
0.010
 Why?
Flaig's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (382) concept(s)
_
Co-Authors Expand Description
See all (46) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)